(Bapineuzumab)Biosimilar Reference Antibody-GS40055

货号：GS40055

Bapineuzumab is a humanized monoclonal antibody (originally murine, IgG1) designed to target amyloid-beta (Aβ) in the brain for the treatment of Alzheimer's disease. It was one of the earliest and most prominent anti-amyloid antibodies to enter large-scale clinical trials. The antibody specifically binds to the N-terminal region of Aβ peptides, with the proposed mechanism of promoting clearance of amyloid plaques from the brain via Fc receptor-mediated phagocytosis by microglia. Despite showing some ability to reduce amyloid plaque burden in Phase II imaging studies, it failed to demonstrate significant clinical benefit (improvement in cognitive or functional outcomes) in multiple Phase III trials. Furthermore, it was associated with significant adverse effects, notably vasogenic cerebral edema (ARIA-E). Its development was subsequently discontinued, marking a major setback for the amyloid hypothesis at the time.